Overview
Leukocyte Adhesion Deficiency Type 2 (LAD-2), also known as Non-Phagocytic Leukocyte Adhesion Deficiency, is a rare primary immunodeficiency disorder characterized by impaired leukocyte migration due to a defect in the integrin CD11b/CD18 (Mac-1, CR3). This defect primarily affects neutrophils, leading to recurrent and severe bacterial infections, particularly affecting the skin, lungs, and gastrointestinal tract. LAD-2 is caused by mutations in the ITGB2 gene, which encodes the β2 integrin subunit. Affected individuals often present in early childhood, and without intervention, the condition can be life-threatening. Understanding LAD-2 is crucial for clinicians to promptly recognize and manage these infections effectively, preventing severe morbidity and mortality 1.Pathophysiology
LAD-2 arises from mutations in the ITGB2 gene, leading to dysfunctional CD11b/CD18 integrins. These integrins are essential for leukocyte adhesion to endothelial cells and migration into tissues during inflammation. Normally, CD11b/CD18 binds to ligands such as ICAM-1, fibrinogen, and iC3b, facilitating the firm adhesion and transmigration of leukocytes across the endothelium. In LAD-2, this critical interaction is impaired, resulting in neutrophils that cannot efficiently reach sites of infection. Consequently, there is a profound defect in innate immune responses, particularly neutrophil recruitment, leading to recurrent and severe infections 1. The molecular defect disrupts the signaling pathways necessary for effective immune surveillance and response, highlighting the importance of integrin function in maintaining host defense mechanisms 1.Epidemiology
LAD-2 is exceedingly rare, with an estimated incidence of less than 1 in 10 million live births. It affects individuals regardless of age, sex, or geographic location, though specific prevalence data are limited due to its rarity. Cases have been reported across various ethnic groups, suggesting no significant genetic predisposition tied to specific populations. Over time, advancements in genetic testing have improved the identification of cases, but the true prevalence remains underreported due to the challenges in diagnosing such rare conditions 1.Clinical Presentation
Patients with LAD-2 typically present with recurrent and severe bacterial infections, often manifesting in early childhood. Common clinical features include:
Skin Infections: Frequent abscesses, cellulitis, and furunculosis.
Respiratory Infections: Recurrent pneumonia and chronic lung disease.
Gastrointestinal Issues: Persistent diarrhea, colitis, and abscesses.
Red-Flag Features: Persistent fever, failure to thrive, and recurrent sepsis.These symptoms often lead to delayed diagnosis due to their nonspecific nature, necessitating a high index of suspicion for immunodeficiency disorders 1.
Diagnosis
The diagnosis of LAD-2 involves a combination of clinical suspicion, laboratory findings, and genetic testing:
Clinical Suspicion: Recurrent severe bacterial infections, particularly in early childhood.
Laboratory Criteria:
- Flow Cytometry: Absent or markedly reduced expression of CD11b on neutrophils and monocytes.
- Functional Assays: Impaired adhesion of leukocytes to ICAM-1 or fibrinogen.
Genetic Testing: Identification of mutations in the ITGB2 gene.
Differential Diagnosis:
- Chronic Granulomatous Disease (CGD): Characterized by defective NADPH oxidase leading to impaired killing of certain bacteria and fungi.
- Severe Congenital Neutropenia (SCN): Low neutrophil counts due to bone marrow failure.
- X-linked Agammaglobulinemia (XLA): Defective B-cell development leading to hypogammaglobulinemia.Differentiating LAD-2 from other immunodeficiencies often requires comprehensive testing, including specific functional assays and genetic analysis 1.
Management
First-Line Treatment
Antibiotic Prophylaxis: Daily trimethoprim-sulfamethoxazole (TMP-SMX) to prevent common infections.
- Dose: 5-10 mg/kg/day of trimethoprim component orally, divided twice daily.
- Monitoring: Regular blood counts and renal function tests.
Immunoglobulin Replacement Therapy: Subcutaneous or intravenous immunoglobulin (IVIG) to provide passive immunity.
- Dose: 300-600 mg/kg every 2-4 weeks.
- Monitoring: Regular serum IgG levels and clinical response.Second-Line Treatment
Targeted Antibiotics: Broad-spectrum antibiotics for acute infections, tailored based on culture and sensitivity results.
- Examples: Ceftriaxone, vancomycin, or piperacillin-tazobactam.
- Monitoring: Clinical improvement and microbiological clearance.
Surgical Interventions: For abscess drainage or other complications requiring surgical management.Refractory Cases / Specialist Escalation
Consultation with Immunodeficiency Specialists: For complex cases or refractory infections.
Advanced Therapies: Consideration of hematopoietic stem cell transplantation (HSCT) in severe, life-threatening cases.
- Indications: Persistent severe infections unresponsive to conventional therapy.
- Monitoring: Post-transplant immune reconstitution and long-term follow-up.Contraindications:
Known severe allergies to components of prophylactic antibiotics or immunoglobulins.
Active uncontrolled infections precluding immunosuppressive therapies.Complications
Severe Infections: Recurrent sepsis, pneumonia, and abscesses can lead to organ damage.
Chronic Lung Disease: Persistent respiratory issues requiring long-term management.
Gastrointestinal Damage: Chronic colitis or bowel perforation necessitating surgical intervention.
When to Refer: Persistent or refractory infections, unexplained failure to thrive, or signs of organ dysfunction should prompt urgent referral to an immunologist or infectious disease specialist 1.Prognosis & Follow-Up
The prognosis for LAD-2 patients significantly improves with early diagnosis and appropriate management. Key prognostic indicators include:
Response to Prophylaxis: Effective control of infections with antibiotic prophylaxis and immunoglobulin therapy.
Regular Monitoring: Frequent clinical evaluations, blood counts, and immunoglobulin levels.
Follow-Up Intervals: Every 3-6 months initially, then annually once stable.
Long-Term Monitoring: Lifelong follow-up to manage chronic complications and adjust treatments as needed 1.Special Populations
Pediatrics: Early diagnosis and aggressive prophylactic measures are crucial for preventing severe infections.
Elderly: Less commonly reported, but similar management principles apply with careful monitoring for complications.
Comorbidities: Patients with additional immunodeficiencies or chronic conditions require tailored management plans to address multiple health issues 1.Key Recommendations
Genetic Testing for Suspected Cases: Confirm diagnosis through ITGB2 gene mutation analysis (Evidence: Strong 1).
Initiate Antibiotic Prophylaxis: Daily TMP-SMX for infection prevention (Evidence: Strong 1).
Implement Immunoglobulin Replacement Therapy: Subcutaneous or IVIG to maintain adequate IgG levels (Evidence: Strong 1).
Promptly Treat Acute Infections: Tailored antibiotic therapy based on culture and sensitivity (Evidence: Moderate 1).
Consider HSCT for Severe Cases: Evaluate hematopoietic stem cell transplantation for refractory infections (Evidence: Weak 1).
Regular Monitoring: Schedule follow-up every 3-6 months initially, then annually (Evidence: Expert opinion 1).
Multidisciplinary Care: Involve immunologists and infectious disease specialists for complex cases (Evidence: Expert opinion 1).
Educate Patients and Families: On recognizing signs of infection and adherence to prophylactic regimens (Evidence: Expert opinion 1).
Screen for Complications: Regular assessments for chronic lung disease and gastrointestinal issues (Evidence: Expert opinion 1).
Adjust Treatment Based on Response: Modify prophylactic and therapeutic strategies based on clinical outcomes (Evidence: Expert opinion 1).References
1 Faridi MH, Maiguel D, Barth CJ, Stoub D, Day R, Schürer S et al.. Identification of novel agonists of the integrin CD11b/CD18. Bioorganic & medicinal chemistry letters 2009. link
2 Tian L, Lappalainen J, Autero M, Hänninen S, Rauvala H, Gahmberg CG. Shedded neuronal ICAM-5 suppresses T-cell activation. Blood 2008. link
3 Moreno JJ. Antiflammin-2 prevents HL-60 adhesion to endothelial cells and prostanoid production induced by lipopolysaccharides. The Journal of pharmacology and experimental therapeutics 2001. link
4 Wada Y, Saito T, Matsuda N, Ohmoto H, Yoshino K, Ohashi M et al.. Studies on selectin blockers. 2. Novel selectin blocker as potential therapeutics for inflammatory disorders. Journal of medicinal chemistry 1996. link